Want to track FOLD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Amicus Therapeutics (FOLD) Q2 Earnings and Revenues Top Estimates
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.15 per share a year ago.
Zacks | 1 year ago
Amicus Therapeutics: Too Cheap At Under $10 A Share
Amicus Therapeutics has recently seen its shares slide under $10, despite strong revenue growth. The company's products, Galafold and Pombiliti + Opfolda, have significant sales potential and are seeing good sales traction. Analyst firms are also largely positive on the company's prospects.
Seekingalpha | 2 years ago
